<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739528</url>
  </required_header>
  <id_info>
    <org_study_id>LEVODESA_04-2017</org_study_id>
    <nct_id>NCT03739528</nct_id>
  </id_info>
  <brief_title>Levo-Dexa vs. Tobra+Dexa for Prevention and Treatment of Inflammation and Prevention of Infection in Cataract Surgery</brief_title>
  <acronym>LEADER7</acronym>
  <official_title>An International, Multicenter, Randomized, Blinded-assessor, Parallel-group Clinical Study Comparing Eye Drops of Combined LEvofloxAcin + DExamethasone foR 7 Days Followed by Dexamethasone Alone for an Additional 7 Days vs. Tobramycin + Dexamethasone for 14 Days for the Prevention and Treatment of Inflammation and Prevention of Infection Associated With Cataract Surgery in Adults - LEADER 7</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NTC srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NTC srl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the non-inferiority of the study treatment&#xD;
      (combined levofloxacin + dexamethasone eye drops) followed by dexamethasone eye drops alone&#xD;
      vs. standard treatment in the prevention and treatment of postoperative ocular inflammation&#xD;
      and prevention of infection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In clinical practice, topical treatment following cataract surgery is frequently administered&#xD;
      using a combination between an antibiotic and a corticosteroid to promote patient adherence&#xD;
      to therapy and to obtain both prevention of infection and treatment of post-surgical&#xD;
      inflammation.&#xD;
&#xD;
      The combination of tobramycin and dexamethasone is among the most widely used combinations,&#xD;
      however, treatment duration and the need for tapering posology over several weeks may favour&#xD;
      the development of bacterial resistance. The study treatment associating a broad-spectrum&#xD;
      antibiotic with a highly effective corticosteroid that can be used for a short period of time&#xD;
      (one week) is therefore of considerable interest.&#xD;
&#xD;
      The aim of this study is to evaluate the non-inferiority of the study treatment, used for a&#xD;
      limited period of time and followed by dexamethasone alone, compared to standard treatment in&#xD;
      preventing and treating ocular inflammation and in preventing post-operative infection while&#xD;
      limiting the emergence of antibiotic resistance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 3, 2018</start_date>
  <completion_date type="Actual">December 19, 2018</completion_date>
  <primary_completion_date type="Actual">December 19, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>A randomized, parallel-group study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Without Signs of Anterior Chamber Inflammation</measure>
    <time_frame>Day 15</time_frame>
    <description>The number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses has been tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS &gt; - Δ. Where πT and πS are the number of participants without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Endophthalmitis</measure>
    <time_frame>Day 4, 8, 15</time_frame>
    <description>The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Without Signs of Anterior Ocular Chamber Inflammation</measure>
    <time_frame>Day 0 (screening), 4, 8</time_frame>
    <description>Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Conjunctival Hyperemia</measure>
    <time_frame>Day 4, 8, 15</time_frame>
    <description>Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Ocular Symptoms Score (TOSS)</measure>
    <time_frame>Day 4, 8, 15</time_frame>
    <description>The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Pain/Discomfort: 4-point Scale</measure>
    <time_frame>Day 4, 8, 15</time_frame>
    <description>Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Rescue Therapy</measure>
    <time_frame>During all the treatment until day 15</time_frame>
    <description>All rescue therapy used following cataract surgery is to be reported at all visits.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Intraocular Pressure (IOP)</measure>
    <time_frame>At day 0 (screening) and at day 4, 8, 15</time_frame>
    <description>IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.</description>
  </other_outcome>
  <other_outcome>
    <measure>Visual Acuity</measure>
    <time_frame>At day 0 (screening) and at day 15</time_frame>
    <description>Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction.&#xD;
Generally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision.&#xD;
Lower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes.</description>
  </other_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>During all the treatment until day 15</time_frame>
    <description>Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group.</description>
  </other_outcome>
  <other_outcome>
    <measure>Global Evaluation of Local Tolerability</measure>
    <time_frame>Day 4, 8, 15</time_frame>
    <description>Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.</description>
  </other_outcome>
  <other_outcome>
    <measure>Burning, Stinging, Blurred Vision</measure>
    <time_frame>Day 4, 8, 15</time_frame>
    <description>Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of Patient Diary (Compliance)</measure>
    <time_frame>Day 15</time_frame>
    <description>Treatment compliance is derived from the number of instillations each day during the study treatment exposure</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">808</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Levofloxacin + Dexamethasone followed by dexamethasone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tobramycin + dexamethasone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin + dexamethasone followed by dexamethasone</intervention_name>
    <description>Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.</description>
    <arm_group_label>Levofloxacin + Dexamethasone followed by dexamethasone</arm_group_label>
    <other_name>Levofloxacin + dexamethasone followed by Maxidex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin + Dexamethasone</intervention_name>
    <description>Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.</description>
    <arm_group_label>Tobramycin + dexamethasone</arm_group_label>
    <other_name>Tobradex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria prior to surgery:&#xD;
&#xD;
          1. Signed written informed consent&#xD;
&#xD;
          2. Male or female, age ≥40 years&#xD;
&#xD;
          3. Scheduled senile or presenile cataract surgery&#xD;
&#xD;
          4. Willing to interrupt the use of contact lenses for the entire duration of the study&#xD;
&#xD;
          5. Able and willing to follow study procedures&#xD;
&#xD;
          6. Female patients must be postmenopausal, surgically sterile or must agree to use an&#xD;
             effective method of contraception&#xD;
&#xD;
             Inclusion criteria following surgery:&#xD;
&#xD;
          7. Surgery completed without complications&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Ocular conditions that at the discretion of the Investigator may interfere with the&#xD;
             efficacy and/or safety evaluations&#xD;
&#xD;
          2. Patients undergoing bilateral cataract surgery&#xD;
&#xD;
          3. Patients under treatment with prostaglandin analogues or intravitreal injections of&#xD;
             anti-vascular endothelial growth factor (VEGF) drugs&#xD;
&#xD;
          4. Systemic diseases that may interfere with the results of the study&#xD;
&#xD;
          5. Any condition that could interfere with correct instillation of eye drops&#xD;
&#xD;
          6. Ocular surgery in the study eye (including laser surgery) in the 3 months before&#xD;
             screening&#xD;
&#xD;
          7. Monocular patients&#xD;
&#xD;
          8. Visual Acuity &lt; 20/80 of the contralateral eye measured as ETDRS or Snellen&#xD;
&#xD;
          9. Contraindications to ocular treatment with Tobradex®, Maxidex® or&#xD;
             levofloxacin/dexamethasone&#xD;
&#xD;
         10. Hypersensitivity to the study product or its excipients&#xD;
&#xD;
         11. Participation in other clinical studies within at least 5 half-lives of the&#xD;
             Investigational Medicinal Product (IMP) used in the previous studies&#xD;
&#xD;
         12. Pregnancy or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Bandello, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ospedale San Raffaele IRCCS S.r.l.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>A.O.U. Osp. Riuniti Umberto I - G.M. Lancisi - G. Salesi - Università degli Studi di Ancona</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale della Murgia &quot;Fabio Perinei&quot; di Altamura</name>
      <address>
        <city>Altamura</city>
        <state>BA</state>
        <zip>70022</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Consorziale di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Bari - Ospedale &quot;Di Venere&quot; - Carbonara di Bari</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniche Gavazzeni S.p.A. - Humanitas Gavazzeni di Bergamo</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. di Bologna - Policlinico S. Orsola-Malpighi di Bologna</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola-Malpighi di Bologna</name>
      <address>
        <city>Bologna</city>
        <state>BO</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST degli Spedali Civili di Brescia - P.O. Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <state>BS</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Franciacorta - P.O. di Chiari</name>
      <address>
        <city>Chiari</city>
        <state>BS</state>
        <zip>25032</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P.O. Ospedale Clinicizzato SS. Annunziata di Chieti</name>
      <address>
        <city>Chieti</city>
        <state>CH</state>
        <zip>66100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Valduce di Como</name>
      <address>
        <city>Como</city>
        <state>CO</state>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico Vittorio Emanuele - P.O. Gaspare Rodolico - Università degli Studi di Catania</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico G.B. Morgagni di Catania - Casa di Cura s.r.l.</name>
      <address>
        <city>Catania</city>
        <state>CT</state>
        <zip>95125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Mater Domini di Catanzaro - Università degli Studi Magna Graecia di Catanzaro</name>
      <address>
        <city>Catanzaro</city>
        <state>CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Casa Sollievo della Sofferenza di San Giovanni Rotondo</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <state>FG</state>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Careggi di Firenze</name>
      <address>
        <city>Firenze</city>
        <state>FI</state>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Policlinico San Martino di Genova</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Policlinico San Martino - Università degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fatebenefratelli - Ospedale &quot;Sacra Famiglia&quot; di Erba</name>
      <address>
        <city>Erba</city>
        <state>LC</state>
        <zip>22036</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. USL Toscana Nord Ovest - Ospedale della Versilia</name>
      <address>
        <city>Lido Di Camaiore</city>
        <state>LU</state>
        <zip>55049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL Toscana Nord Ovest - P.O. San Luca di Lucca</name>
      <address>
        <city>San Filippo</city>
        <state>LU</state>
        <zip>56123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico &quot;G. Martino&quot; di Messina</name>
      <address>
        <city>Messina</city>
        <state>ME</state>
        <zip>98124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASP di Messina - P.O. &quot;Giuseppe Fogliani&quot; di Milazzo</name>
      <address>
        <city>Milazzo</city>
        <state>ME</state>
        <zip>98057</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Ovest Milanese - Ospedale Civile di Legnano</name>
      <address>
        <city>Legnano</city>
        <state>MI</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gruppo Multimedica - Ospedale San Giuseppe di Milano</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele IRCCS S.r.l.</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST Fatebenefratelli Sacco - Università degli Studi di Milano - Ospedale L. Sacco</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20157</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas di Rozzano</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASST di Melegnano e della Martesana - Ospedale di Vizzolo Predabissi</name>
      <address>
        <city>Vizzolo Predabissi</city>
        <state>MI</state>
        <zip>20077</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico di Modena - Università degli Studi di Modena e Reggio Emilia</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41125</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale di Sassuolo</name>
      <address>
        <city>Sassuolo</city>
        <state>MO</state>
        <zip>41049</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Polispecialistico Monterosso di Carrara</name>
      <address>
        <city>Carrara</city>
        <state>MS</state>
        <zip>54033</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Policlinico &quot;P. Giaccone&quot; di Palermo</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. &quot;Ospedali Riuniti Villa Sofia-Cervello&quot; di Palermo - P.O. &quot;Villa Sofia&quot; di Palermo</name>
      <address>
        <city>Palermo</city>
        <state>PA</state>
        <zip>90146</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AUSL di Piacenza - Ospedale &quot;Guglielmo da Saliceto&quot; di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>Piacenza</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. ULSS 6 Euganea - Ospedali Riuniti Padova Sud - Ospedale Madre Teresa di Calcutta-Schiavonia</name>
      <address>
        <city>Monselice</city>
        <state>PD)</state>
        <zip>35043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. ULSS 6 Euganea - Ospedale S. Antonio - Centro Oculistico San Paolo di Padova</name>
      <address>
        <city>Padova</city>
        <state>PD</state>
        <zip>35100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. di Perugia - Ospedale S. Maria della Misericordia di Perugia</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06156</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo - Università degli Studi di Pavia</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli di Reggio Calabria</name>
      <address>
        <city>Reggio Calabria</city>
        <state>RC</state>
        <zip>89124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-medico di Roma</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione PTV Policlinico Tor Vergata</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Sant'Andrea di Roma</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Fondazione G.B. Bietti di Roma</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00198</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ASL Roma 4 - Ospedale San Paolo di Civitavecchia</name>
      <address>
        <city>Civitavecchia</city>
        <state>RN</state>
        <zip>00053</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. ULSS 5 Polesana - Ospedale &quot;Santa Maria della Misericordia&quot;</name>
      <address>
        <city>Rovigo</city>
        <state>RO</state>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U Città della Salute e della Scienza di Torino - Ospedale Molinette</name>
      <address>
        <city>Torino</city>
        <state>TO</state>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Sanitaria Universitaria Integrata di Trieste - Ospedali Riuniti di Trieste - Ospedale Maggiore</name>
      <address>
        <city>Trieste</city>
        <state>TS</state>
        <zip>34129</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. ULSS 2 Marca Trevigiana - Ospedale di Treviso</name>
      <address>
        <city>Treviso</city>
        <state>TV</state>
        <zip>31100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Sanitaria Universitaria Integrata di Udine - P.O. Universitario &quot;Santa Maria della Misericordia&quot; diUdine</name>
      <address>
        <city>Udine</city>
        <state>UD</state>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. ULSS 7 Pedemontana - Ospedale San Bassiano di Bassano del Grappa</name>
      <address>
        <city>Bassano Del Grappa</city>
        <state>VI</state>
        <zip>36061</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Sacro Cuore - Don Calabria di Negrar</name>
      <address>
        <city>Negrar</city>
        <state>VR</state>
        <zip>37024</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Integrata di Verona - Ospedale Borgo Roma</name>
      <address>
        <city>Verona</city>
        <state>VR</state>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az. Osp. di Rilievo Nazionale &quot;A. Cardarelli&quot; di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. &quot;Maggiore della Carità&quot; di Novara</name>
      <address>
        <city>Novara</city>
        <zip>28100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O.U. Senese - Università degli Studi di Siena</name>
      <address>
        <city>Siena</city>
        <zip>53100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 9, 2018</study_first_submitted>
  <study_first_submitted_qc>November 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <results_first_submitted>May 29, 2020</results_first_submitted>
  <results_first_submitted_qc>August 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 18, 2020</results_first_posted>
  <last_update_submitted>August 4, 2020</last_update_submitted>
  <last_update_submitted_qc>August 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 12, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT03739528/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Study period:&#xD;
Date of first enrolment: 03.09.2018&#xD;
Date study finalized (LPLV): 19.12.2018&#xD;
Study centers:&#xD;
42 centers in Italy&#xD;
4 centers in Spain&#xD;
4 centers in Russia&#xD;
1 center in Germany</recruitment_details>
      <pre_assignment_details>Planned sample size n.800; randomized patients n.808; screened patients n.863</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
          <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day.</description>
        </group>
        <group group_id="P2">
          <title>Tobramycin + Dexamethasone</title>
          <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="403"/>
                <participants group_id="P2" count="405"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Treatment</title>
              <participants_list>
                <participants group_id="P1" count="395"/>
                <participants group_id="P2" count="393"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="388"/>
                <participants group_id="P2" count="388"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment and study discontinued</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Treatment discontinued + study completed</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
      <group_list>
        <group group_id="B1">
          <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
          <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day.</description>
        </group>
        <group group_id="B2">
          <title>Tobramycin + Dexamethasone</title>
          <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="395"/>
            <count group_id="B2" value="393"/>
            <count group_id="B3" value="788"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="141"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="322"/>
                    <measurement group_id="B3" value="647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.12" spread="8.55"/>
                    <measurement group_id="B2" value="71.84" spread="8.64"/>
                    <measurement group_id="B3" value="71.98" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="239"/>
                    <measurement group_id="B3" value="468"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="320"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="393"/>
                    <measurement group_id="B2" value="391"/>
                    <measurement group_id="B3" value="784"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Without Signs of Anterior Chamber Inflammation</title>
        <description>The number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses has been tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS &gt; - Δ. Where πT and πS are the number of participants without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.</description>
        <time_frame>Day 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day.</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Without Signs of Anterior Chamber Inflammation</title>
          <description>The number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0). The following non-inferiority hypotheses has been tested: H0 : πT - πS ≤ - Δ; H1 : πT - πS &gt; - Δ. Where πT and πS are the number of participants without signs of anterior chamber inflammation in the test and standard treatments, respectively, and the non-inferiority margin is Δ = 10%.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Number of participants without signs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="376"/>
                    <measurement group_id="O2" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of participants with signs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Endophthalmitis</title>
        <description>The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.</description>
        <time_frame>Day 4, 8, 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set).&#xD;
This outcome was not analyzed by applying the Last Observation Carried Forward (LOCF) method to impute missing values if at least one post-baseline value was available.</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day.</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Endophthalmitis</title>
          <description>The number of participants with endophthalmitis after administration of study treatment in the study was assessed and reported. Diagnosis of endophthalmitis is based on clinical evaluation of signs and symptoms (such as swollen eyelids, ocular pain, conjunctival hyperemia, decreased visual acuity, opaque vitreous) through slit lamp examination, and microbiological tests on conjunctival or corneal swabs.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set).&#xD;
This outcome was not analyzed by applying the Last Observation Carried Forward (LOCF) method to impute missing values if at least one post-baseline value was available.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 3 - Day 4: no diagnosis of endophthalmitis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="393"/>
                    <measurement group_id="O2" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 - Day 8: no diagnosis of endophthalmitis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="391"/>
                    <count group_id="O2" value="393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="391"/>
                    <measurement group_id="O2" value="393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 - Day 15: no diagnosis of endophthalmitis</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="389"/>
                    <count group_id="O2" value="391"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="389"/>
                    <measurement group_id="O2" value="391"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Without Signs of Anterior Ocular Chamber Inflammation</title>
        <description>Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0).</description>
        <time_frame>Day 0 (screening), 4, 8</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Without Signs of Anterior Ocular Chamber Inflammation</title>
          <description>Number of participants without signs of anterior chamber inflammation (sum of cells and flare score = 0).</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 - Screening</title>
              <category_list>
                <category>
                  <title>Number of participants without signs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="395"/>
                    <measurement group_id="O2" value="393"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of participants with signs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 - Day 4</title>
              <category_list>
                <category>
                  <title>Number of participants without signs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                    <measurement group_id="O2" value="302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of participants with signs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 - Day 8</title>
              <category_list>
                <category>
                  <title>Number of participants without signs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="341"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Number of participants with signs</title>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Conjunctival Hyperemia</title>
        <description>Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).</description>
        <time_frame>Day 4, 8, 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Conjunctival Hyperemia</title>
          <description>Conjunctival hyperemia was evaluated with slit lamp and results provided as a score as follows: 0 = absence of inflammation, 1 = mild inflammation (some vessels injected), 2 = moderate inflammation (diffuse injection of vessels, but individual vessels are still discernable) 3 = severe inflammation (intense injection of vessels, individual vessels not easily discernable).</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 3 - Day 4</title>
              <category_list>
                <category>
                  <title>Score=0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="337"/>
                    <measurement group_id="O2" value="323"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score&gt;0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 - Day 8</title>
              <category_list>
                <category>
                  <title>Score=0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="348"/>
                    <measurement group_id="O2" value="358"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score&gt;0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 - Day 15</title>
              <category_list>
                <category>
                  <title>Score=0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="371"/>
                    <measurement group_id="O2" value="375"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score&gt;0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Ocular Symptoms Score (TOSS)</title>
        <description>The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe.</description>
        <time_frame>Day 4, 8, 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day.</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Total Ocular Symptoms Score (TOSS)</title>
          <description>The TOSS is a patient-reported evaluation in the TOSS Questionnaire of 3 ocular symptoms: itching/burning, hyperemia of conjunctiva and tearing. A score was given in the presence of symptoms: 0 = none, 1 = mild, 2 = moderate, 3 = severe.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 3 - Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.29" spread="0.63"/>
                    <measurement group_id="O2" value="0.37" spread="0.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 - Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.28" spread="0.67"/>
                    <measurement group_id="O2" value="0.26" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 - Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.17" spread="0.49"/>
                    <measurement group_id="O2" value="0.17" spread="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ocular Pain/Discomfort: 4-point Scale</title>
        <description>Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).</description>
        <time_frame>Day 4, 8, 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Ocular Pain/Discomfort: 4-point Scale</title>
          <description>Overall ocular pain and discomfort was evaluated by the subject on a 4-point scale (0 = absent, 1 = mild, 2 = moderate, 3 = severe).</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 3 - Day 4: Presence/absence of ocular pain</title>
              <category_list>
                <category>
                  <title>Score=0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="360"/>
                    <measurement group_id="O2" value="361"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score&gt;0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 - Day 8: Presence/absence of ocular pain</title>
              <category_list>
                <category>
                  <title>Score=0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="366"/>
                    <measurement group_id="O2" value="366"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score&gt;0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 - Day 15: Presence/absence of ocular pain</title>
              <category_list>
                <category>
                  <title>Score=0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="377"/>
                    <measurement group_id="O2" value="373"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Score&gt;0</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Rescue Therapy</title>
        <description>All rescue therapy used following cataract surgery is to be reported at all visits.</description>
        <time_frame>During all the treatment until day 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Rescue Therapy</title>
          <description>All rescue therapy used following cataract surgery is to be reported at all visits.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Patients with rescue therapy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="392"/>
                    <measurement group_id="O2" value="392"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Patients with no rescue therapy</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Intraocular Pressure (IOP)</title>
        <description>IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.</description>
        <time_frame>At day 0 (screening) and at day 4, 8, 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Intraocular Pressure (IOP)</title>
          <description>IOP is measured using a tonometer. IOP is measured as mmHg; normal intraocular pressures average between 12-22 mm Hg.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 - Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.16" spread="2.48"/>
                    <measurement group_id="O2" value="15.12" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3 - Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.26" spread="2.73"/>
                    <measurement group_id="O2" value="14.49" spread="2.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 - Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.29" spread="2.51"/>
                    <measurement group_id="O2" value="14.45" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 - Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.45" spread="2.65"/>
                    <measurement group_id="O2" value="14.37" spread="2.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Visual Acuity</title>
        <description>Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction.&#xD;
Generally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision.&#xD;
Lower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes.</description>
        <time_frame>At day 0 (screening) and at day 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day.</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Acuity</title>
          <description>Visual acuity was assessed as per local clinical practice, i.e. with the Snellen (feet) or the ETDRS (meter) chart. Visual acuity was then analysed using decimal unit. Decimal score is the decimal expression of the Snellen (feet) or the ETDRS (meter) charts in which the numerator indicates the distance from the chart and the denominator indicates the size of the smallest line that can be read. Decimal values were provided directly from the investigator or computed as a result of the Snellen or ETDRS fraction.&#xD;
Generally decimal values from 0.01 to 0.10 indicate severe vision loss; decimal values from 0.125 to 0.25 indicate moderate vision loss; decimal values from 0.32 to 0.63 indicate mild vision loss; decimal values from 0.8 to 1.6 indicate normal vision.&#xD;
Lower decimal values correspond to a reduced visual acuity and worst outcomes, while higher decimal values indicate an improved visual acuity and better outcomes.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>decimal score</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1 - Screening</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.41" spread="0.23"/>
                    <measurement group_id="O2" value="0.41" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 - Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.88" spread="0.19"/>
                    <measurement group_id="O2" value="0.89" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Adverse Events</title>
        <description>Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group.</description>
        <time_frame>During all the treatment until day 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin 5 mg/ml+Dexamethasone 1 mg/ml (7 days,1 drop/4 times a day) followed by dexamethasone 1 mg/ml (7 days,1 drop/4 times a day).&#xD;
Levofloxacin + dexamethasone followed by dexamethasone: Levofloxacin + dexamethasone ophthalmic solution for 7 days, 1 drop - 4 times a day, followed by dexamethasone ophthalmic suspension (Maxidex®) for an additional 7 days, 1 drop - 4 times a day.</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin + dexamethasone (14 days, 1 drop/4 times a day).&#xD;
Tobramycin + Dexamethasone: Tobramycin + dexamethasone ophthalmic suspension (Tobradex®) for 14 days, 1 drop - 4 times a day.</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>Adverse events were described according to System Organ Classes (SOC) and Preferred Terms (PT) using the Medical Dictionary for Regulatory Activities (MedDRA) and were presented by treatment group.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients with TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs suspected to be study related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with TEAEs leading to discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with fatal TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients with severe TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Global Evaluation of Local Tolerability</title>
        <description>Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.</description>
        <time_frame>Day 4, 8, 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Global Evaluation of Local Tolerability</title>
          <description>Global evaluation was evaluated on a 4-point scale: 0 = no intolerability, 1 = mild intolerability, 2 = moderate intolerability, 3 = maximum intolerability.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 3 - Day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.21"/>
                    <measurement group_id="O2" value="0.01" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4 - Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" spread="0.11"/>
                    <measurement group_id="O2" value="0.03" spread="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 5 - Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" spread="0.15"/>
                    <measurement group_id="O2" value="0.02" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Burning, Stinging, Blurred Vision</title>
        <description>Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.</description>
        <time_frame>Day 4, 8, 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Burning, Stinging, Blurred Vision</title>
          <description>Burning, stinging, blurred vision were evaluated on a 4-point scale: 0 = none, 1 = mild, 2 = moderate, 3 = severe.</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Burning: visit 3 - day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" spread="0.27"/>
                    <measurement group_id="O2" value="0.09" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning: visit 4 - day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.24"/>
                    <measurement group_id="O2" value="0.11" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Burning: visit 5 - day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.29"/>
                    <measurement group_id="O2" value="0.07" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stinging: visit 3 - day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.05" spread="0.23"/>
                    <measurement group_id="O2" value="0.04" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stinging: visit 4 - day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="0.29"/>
                    <measurement group_id="O2" value="0.07" spread="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stinging: visit 5 - day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.26"/>
                    <measurement group_id="O2" value="0.04" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred vision: visit 3 - day 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.27"/>
                    <measurement group_id="O2" value="0.05" spread="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred vision: visit 4 - day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.06" spread="0.25"/>
                    <measurement group_id="O2" value="0.04" spread="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blurred vision: visit 5 - day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.20"/>
                    <measurement group_id="O2" value="0.01" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Assessment of Patient Diary (Compliance)</title>
        <description>Treatment compliance is derived from the number of instillations each day during the study treatment exposure</description>
        <time_frame>Day 15</time_frame>
        <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
        <group_list>
          <group group_id="O1">
            <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
            <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day.</description>
          </group>
          <group group_id="O2">
            <title>Tobramycin + Dexamethasone</title>
            <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Patient Diary (Compliance)</title>
          <description>Treatment compliance is derived from the number of instillations each day during the study treatment exposure</description>
          <population>The analysis population is represented by all randomized patients who received at least one dose of study treatment (Full Analysis Set)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="395"/>
                <count group_id="O2" value="393"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>No missed dose</title>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="332"/>
                  </measurement_list>
                </category>
                <category>
                  <title>One missed dose per day or three missed doses per</title>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt; 1 missed dose per day or &gt; 3 missed doses per we</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From baseline to the end of the treatment, corresponding to 15 days</time_frame>
      <desc>It is not possible to attribute Adverse Events to Dexamethasone alone following treatment with Levofloxacin + Dexamethasone</desc>
      <group_list>
        <group group_id="E1">
          <title>Levofloxacin + Dexamethasone Followed by Dexamethasone</title>
          <description>Levofloxacin + dexamethasone ophthalmic solution containing levofloxacin hemihydrate 5.12 mg/ml, corresponding to levofloxacin 5 mg/ml, and dexamethasone sodium phosphate 1.32 mg/ml, corresponding to dexamethasone 1 mg/ml (L-DSP), followed by Dexamethasone 1 mg/ml ophthalmic suspension (Maxidex)&#xD;
Dose and regimen: Levofloxacin + dexamethasone sodium phosphate eye drops for 7 days, 1 x 30 μl drop - 4 times a day, followed by dexamethasone eye drops (Maxidex) for an additional 7 days, 1 drop - 4 times a day.</description>
        </group>
        <group group_id="E2">
          <title>Tobramycin + Dexamethasone</title>
          <description>Tobramycin 3 mg/ml + dexamethasone 1 mg/ml eye drops suspension (Tobradex)&#xD;
Dose and regimen: 1 drop - 4 times a day for 14 days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="388"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="388"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="388"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="388"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="395"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="393"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alessandro Colombo</name_or_title>
      <organization>NTC srl</organization>
      <phone>+390243850490</phone>
      <email>alessandro.colombo@ntcpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

